These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15240516)

  • 41. Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death.
    Ejeskär K; Krona C; Carén H; Zaibak F; Li L; Martinsson T; Ioannou PA
    BMC Cancer; 2005 Dec; 5():161. PubMed ID: 16359544
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma.
    Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Scheibenbogen C; Thiel E; Foerster MH; Keilholz U
    Clin Cancer Res; 2007 Feb; 13(4):1171-8. PubMed ID: 17317826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
    Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
    Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epigenetic regulation of PRAME gene in chronic myeloid leukemia.
    Roman-Gomez J; Jimenez-Velasco A; Agirre X; Castillejo JA; Navarro G; Jose-Eneriz ES; Garate L; Cordeu L; Cervantes F; Prosper F; Heiniger A; Torres A
    Leuk Res; 2007 Nov; 31(11):1521-8. PubMed ID: 17382387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathologic assessment of melanoma sentinel nodes: a role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA.
    Abrahamsen HN; Sorensen BS; Nexo E; Hamilton-Dutoit SJ; Larsen J; Steiniche T
    Clin Cancer Res; 2005 Feb; 11(4):1425-33. PubMed ID: 15746042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.
    Gure AO; Chua R; Williamson B; Gonen M; Ferrera CA; Gnjatic S; Ritter G; Simpson AJ; Chen YT; Old LJ; Altorki NK
    Clin Cancer Res; 2005 Nov; 11(22):8055-62. PubMed ID: 16299236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
    Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
    Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer.
    Mecklenburg I; Weckermann D; Zippelius A; Schoberth A; Petersen S; Prang N; Riethmüller G; Kufer P
    J Immunol Methods; 2007 Jun; 323(2):180-93. PubMed ID: 17540401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression and prognostic relevance of PRAME in primary osteosarcoma.
    Tan P; Zou C; Yong B; Han J; Zhang L; Su Q; Yin J; Wang J; Huang G; Peng T; Shen J
    Biochem Biophys Res Commun; 2012 Mar; 419(4):801-8. PubMed ID: 22390931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma.
    Proto-Siqueira R; Figueiredo-Pontes LL; Panepucci RA; Garcia AB; Rizzatti EG; Nascimento FM; Ishikawa HC; Larson RE; Falcão RP; Simpson AJ; Gout I; Filonenko V; Rego EM; Zago MA
    Leuk Res; 2006 Nov; 30(11):1333-9. PubMed ID: 16620968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma.
    Ahlén J; Wejde J; Brosjö O; von Rosen A; Weng WH; Girnita L; Larsson O; Larsson C
    Clin Cancer Res; 2005 Jan; 11(1):206-16. PubMed ID: 15671548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma.
    Ercolak V; Paydas S; Bagir E; Ergin M; Seydaoglu G; Celik H; Yavu B; Tanriverdi K; Gunaldi M; Afsar CU; Duman BB
    Acta Haematol; 2015; 134(4):199-207. PubMed ID: 26044287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia.
    Tajeddine N; Millard I; Gailly P; Gala JL
    Clin Chem Lab Med; 2006; 44(5):548-55. PubMed ID: 16681423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
    Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
    J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis.
    Zou C; Shen J; Tang Q; Yang Z; Yin J; Li Z; Xie X; Huang G; Lev D; Wang J
    Cancer; 2012 Apr; 118(7):1845-55. PubMed ID: 22009167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.
    Carlin S; Mairs RJ; McCluskey AG; Tweddle DA; Sprigg A; Estlin C; Board J; George RE; Ellershaw C; Pearson AD; Lunec J; Montaldo PG; Ponzoni M; van Eck-Smit BL; Hoefnagel CA; van den Brug MD; Tytgat GA; Caron HN
    Clin Cancer Res; 2003 Aug; 9(9):3338-44. PubMed ID: 12960120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis.
    Krams M; Parwaresch R; Sipos B; Heidorn K; Harms D; Rudolph P
    Oncogene; 2004 Jan; 23(2):588-95. PubMed ID: 14724587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biological aspects of neuroblastomas identified by mass screening in Quebec.
    Brodeur GM; Look AT; Shimada H; Hamilton VM; Maris JM; Hann HW; Leclerc JM; Bernstein M; Brisson LC; Brossard J; Lemieux B; Tuchman M; Woods WG
    Med Pediatr Oncol; 2001 Jan; 36(1):157-9. PubMed ID: 11464873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia.
    Steinbach D; Pfaffendorf N; Wittig S; Gruhn B
    Cancer Genet Cytogenet; 2007 Aug; 177(1):51-4. PubMed ID: 17693191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.